PBYI
Puma Biotechnology, Inc.·Healthcare
7.31
0.550%(+0.04)
Close PriceLast Updated: — ET
52W L: $3.0352W H: $7.90
PBYI NEWS
marketbeat.com
May 8
Puma Biotechnology Q1 Earnings Call Highlights
Puma Biotechnology NASDAQ: PBYI reported first-quarter 2026 total revenue of $44.8 million, driven primarily by NERLYNX product revenue net of $42.0 million and royalty revenue of $2.8 million, according to remarks on the company's earnings call. Management attributed the quarter's product revenue performance in part to a specialty pharmacy and distributor inventory drawdown and highlighted new interim clinical data from ongoing Phase II alisertib studies in small cell lung cancer and HER2-negative, hormone receptor-positive breast cancer.
zacks.com
May 8
PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotechnology beats Q1 earnings and revenue estimates while raising its 2026 outlook.
seekingalpha.com
May 8
Puma Biotechnology, Inc. (PBYI) Q1 2026 Earnings Call Transcript
Puma Biotechnology, Inc. (PBYI) Q1 2026 Earnings Call Transcript
zacks.com
May 7
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates
Puma Biotech (PBYI) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to earnings of $0.1 per share a year ago.
businesswire.com
May 7
Puma Biotechnology Reports First Quarter 2026 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology hosted a conference call and provided a corporate update on May 7, 2026, following release of its 1Q-2026 financial results.
businesswire.com
May 6
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported inducement awards granted to six new hires in April 2026, as required under Nasdaq Listing Rule 5635(c)(4) .
